FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo

This study aimed to test whether [(18)F]fluoro-D-glucose (FDG) uptake of tumours measured by positron emission tomography (PET) can be used as surrogate marker to define the optimal biological dose (OBD) of mTOR inhibitors in vivo. Everolimus at 0.05, 0.5, 5 and 15 mg kg(−1) per day was administered...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Cejka, D, Kuntner, C, Preusser, M, Fritzer-Szekeres, M, Fueger, B J, Strommer, S, Werzowa, J, Fuereder, T, Wanek, T, Zsebedics, M, Mueller, M, Langer, O, Wacheck, V
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2009
Teme:
Translational Therapeutics
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2695687/
https://ncbi.nlm.nih.gov/pubmed/19436299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605076
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki